Envestnet Asset Management Inc. reduced its stake in shares of uniQure (NASDAQ:QURE – Get Rating) by 6.5% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 56,396 shares of the biotechnology company’s stock after selling 3,938 shares during the period. Envestnet Asset Management Inc.’s holdings in uniQure were worth $1,051,000 as of its most recent filing with the SEC.
Several other hedge funds have also recently bought and sold shares of the stock. BlackRock Inc. raised its holdings in uniQure by 1.7% during the 1st quarter. BlackRock Inc. now owns 4,366,736 shares of the biotechnology company’s stock worth $78,908,000 after buying an additional 72,931 shares during the period. State Street Corp raised its holdings in uniQure by 30.4% during the 1st quarter. State Street Corp now owns 2,813,416 shares of the biotechnology company’s stock worth $50,838,000 after buying an additional 655,732 shares during the period. Vanguard Group Inc. raised its holdings in uniQure by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 1,209,840 shares of the biotechnology company’s stock worth $21,861,000 after buying an additional 30,053 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of uniQure by 22.8% in the first quarter. JPMorgan Chase & Co. now owns 884,820 shares of the biotechnology company’s stock valued at $15,989,000 after purchasing an additional 164,069 shares during the last quarter. Finally, Privium Fund Management B.V. raised its holdings in shares of uniQure by 4.9% in the first quarter. Privium Fund Management B.V. now owns 493,229 shares of the biotechnology company’s stock valued at $8,913,000 after purchasing an additional 23,196 shares during the last quarter. 86.46% of the stock is currently owned by institutional investors and hedge funds.
uniQure Price Performance
Shares of QURE opened at $26.36 on Thursday. The company has a market cap of $1.23 billion, a price-to-earnings ratio of -9.80 and a beta of 0.96. uniQure has a 1-year low of $12.52 and a 1-year high of $30.41. The company’s fifty day simple moving average is $19.61 and its 200 day simple moving average is $19.08. The company has a current ratio of 7.26, a quick ratio of 7.20 and a debt-to-equity ratio of 0.24.
Insiders Place Their Bets
Wall Street Analysts Forecast Growth
A number of research firms have recently issued reports on QURE. The Goldman Sachs Group lifted their price objective on shares of uniQure from $47.00 to $57.00 and gave the company a “buy” rating in a report on Wednesday. StockNews.com began coverage on shares of uniQure in a report on Wednesday, October 12th. They issued a “sell” rating on the stock. Truist Financial lifted their price objective on shares of uniQure from $51.00 to $65.00 in a report on Wednesday. Wells Fargo & Company lowered their price objective on shares of uniQure from $34.00 to $24.00 and set an “equal weight” rating on the stock in a report on Tuesday, August 9th. Finally, William Blair reiterated an “outperform” rating on shares of uniQure in a report on Wednesday, November 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $48.71.
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis.
- Get a free copy of the StockNews.com research report on uniQure (QURE)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.